Tert-Butyl Formate

Tert-Butyl Formate

SCHEMBL27722006

C1CNCCN1.CC(C)(C)OC=O.Cl.Cl

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ESR1

The experimentally established mechanism targets of Tert-Butyl Formate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.65
HIF1A Q16665 1/20 0.30
MAPT P10636 1/20 0.30
PDE4A P27815 1/20 0.30
KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tert-Butyl Formate SCHEMBL27606011 1.00 TDP1 (0.65) TDP1HIF1AMAPTPDE4AKDR
Tert-Butyl Formate SCHEMBL28092916 0.97 TDP1 (0.68) TDP1HIF1AMAPTPDE4AKDR
Tert-Butyl Formate SCHEMBL27473155 0.97 TDP1 (0.68) TDP1HIF1AMAPTPDE4AKDR
Tert-Butyl Formate SCHEMBL28331255 0.97 TDP1 (0.68) TDP1HIF1AMAPTPDE4AKDR
Tert-Butyl Formate SCHEMBL28256721 0.95 TDP1 (0.65) TDP1HIF1AMAPTPDE4AKDR
Tert-Butyl Formate SCHEMBL28055962 0.91 TDP1 (0.59) TDP1
Tert-Butyl Formate SCHEMBL28000511 0.91 TDP1 (0.59) TDP1
Tert-Butyl Formate SCHEMBL28147817 0.91 TDP1 (0.59) TDP1
Tert-Butyl Formate SCHEMBL27853345 0.89 TDP1 (0.56) TDP1
Tert-Butyl Formate SCHEMBL27565884 0.88 TDP1 (0.62) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101309918-B [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases LILLY CO ELI 2010-12-29 CN disclosed
CN-101309918-A [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases LILLY CO ELI (US) 2008-11-19 CN disclosed